Background. The literature on the involvement of mannose-binding lectin (MBL) in human immunodeficiency virus (HIV) transmission and acquired immunodeficiency syndrome (AIDS) is conflicting. Polymorphisms in the MBL2 gene reduce the level of protein and alter its structure. Thus, we investigated whether MBL2 alleles and plasma concentrations of MBL are associated with perinatal HIV transmission and disease progression.
Mannose-binding lectin (MBL) is a collectin synthesized by the liver and secreted into the bloodstream, where it plays an important role in the innate immune defense against invading microorganisms [1] . MBL is a plasma pattern-recognition receptor that can mediate the elimination of pathogens, either as an opsonin that promotes phagocytosis or by direct killing via complement activation through the MBL-associated serine proteases (MASP-1, -2, and -3) [2] . This lectin pathway takes place through the recognition of and binding to an array of repetitive, specific carbohydrates typical of microbial surfaces, such as D-mannose, glucose, L-fucose, maltose, N-acetylglucosamine, and N-acetylmannosamine, but not galactose or sialic acid [3, 4] . It is believed that, of the 3 MASPs, MASP-2 is the key enzyme that mediates the complement attack. When MBL complexed with MASP-2 binds to sugar arrays, the MBL-MASP-2 proenzyme is activated and cleaves sequentially the C4 and C2 components of the complement, generating the C4b2a complex, a potent C3 convertase [5] . It has been suggested that the MBL-MASP-1 complex directly activates C3 [6] .
MBL has an oligomeric structure of 2-6 subunits, wherein each subunit comprises 3 identical polypeptides in a triple helix structure (recently reviewed in [7] ). In circulation, MBL is composed mainly of trimers and tetramers, but higher (pentamers and hexamers) and lower oligomeric forms may also be found. A deficiency of normally oligomerized MBL may be associated with increased sus-ceptibility to several pathogens, particularly when the adaptative immune system is immature (as in early childhood) or has been suppressed (e.g., by genetic or acquired immunodeficiency, after organ transplantation, or during cancer chemotherapy) [8 -10] . In addition, MBL deficiency has also been associated with a more severe course of autoimmune diseases, such as systemic lupus erythematosus [11] [12] [13] and rheumatoid arthritis [14] .
A decrease of functional MBL in circulation is caused by mutations in the coding and noncoding regions of the MBL gene (MBL2). In the coding region, 3 independent point mutations in exon 1 have been reported, including the substitution of glycine with aspartic acid at codon 54 [15] , glycine with glutamic acid at codon 57 [16] , and cysteine with arginine at codon 52 [17] . These mutations generate the allelic variants named B, C, and D, respectively, usually designated collectively as O; the wild-type allele is called A. In homozygotes or compound heterozygotes undetectable protein levels are found, whereas in heterozygotes the most profound effect is seen for the B and C alleles. The O variants seem to affect the oligomerization of the polypeptide chains, MBL secretion in serum, or even the turnover rate of serum MBL. Consequently, MBL variants trigger a defective activation of complement, owing to an altered distribution of oligomers and the inability of MBL to bind to the MASPs [2] .
The distribution of MBL2 alleles varies widely among different populations. The B allele is present in white, Asian, and American indigenous populations, with proportions ranging from 11% to 46% [18 -21] . The C allele is found almost exclusively in African populations (24%-32%) [16, 19] , and the D allele is the least common variant (Ͻ5%), being found in white persons and East Africans and almost absent in Asians. Three additional polymorphisms have been found in the promoter region of MBL2, at positions Ϫ550 (H/L) and Ϫ221 (X/Y) and in the 5' untranslated region of exon 1 at position ϩ4 (P/Q) [18] . Although all of the promoter variants may affect the concentration of circulating MBL, the major effect is observed with the X variant, which is found only on a wild-type A background. Through polymorphisms in the coding and noncoding variants, MBL levels can vary 1000-fold in apparently healthy individuals, and these MBL2 variants are found at remarkably high frequencies in all ethnic groups [22, 23] . However, why the majority of MBL-deficient individuals do not acquire repeated infections is unknown; it is probably because of the redundancy of the complement system and might even indicate that MBL2 allelic variants are not exclusively disadvantageous.
The participation of MBL in HIV-1 infection has been evaluated in several studies, but its role still remains controversial. In vitro studies have shown a direct interaction between MBL and HIV. It has been reported that (1) high-mannose oligosaccharides present on the gp120 of HIV-1 are recognized as ligands for MBL [24] , (2) the binding of MBL to gp120 allows the activation of the complement system [25] , and (3) MBL can selectively bind to HIV-1-infected cells and inhibit the viral infection of CD4 ϩ T cell lines at physiologically relevant MBL concentrations [26] . These findings suggest that MBL might play a direct role in HIV-1 infection, through a mechanism yet to be identified.
The aim of the present study was to establish the genotypic frequencies of coding and noncoding MBL2 variants in a whiteHispanic population of Argentina and to evaluate their role in HIV-1 vertical transmission and progression to AIDS in infected children.
METHODS

Study population.
The study was performed in a whiteHispanic population of Argentina and included stored genomic DNA obtained from 147 healthy blood donors (control group) and 345 children perinatally exposed to HIV-1 (pediatric cohort) from the Hospital de Pediatría "Juan P. Garrahan" (Buenos Aires, Argentina), a national pediatric referral hospital. The Ethics Committee and the Institutional Review Board of the hospital approved the study. Written informed consent was obtained from the parents or legal guardians of the patients and from the blood donors. The pediatric cohort included 184 exposed uninfected (EU) and 161 HIV-1-infected children born to HIV-1-seropositive mothers between 1985 and 2001. HIV-1 infection status and AIDS were defined according to the 1994 criteria of the US Centers for Disease Control and Prevention classification for children [27] . Eighty-six mother-infant pairs (78 EU and 8 HIV-infected) received the 3-part Pediatric AIDS Clinical Trials Group Protocol 076 zidovudine regimen [28] , and for 22 pairs (12 EU and 10 HIV infected) zidovudine was given both to the mother during delivery and to the newborn. A total of 235 children (94 EU and 141 HIV infected) did not receive zidovudine, and for 2 infected children the information was unavailable. Survival analysis of HIV-1-infected children was restricted to 130 children with recorded clinical follow-up. The median follow-up time was 96.5 months (range, 2-221 months); 42% of the HIV-infected children progressed to AIDS, and 5% died during the study period, which ended February 2006. The differences in the numbers of patients analyzed for each locus were due to a lack of polymerase chain reaction (PCR) amplification as well as a dearth of samples.
Genotyping analysis. PCR assays were performed directly on peripheral blood mononuclear cell lysates or DNA samples. Genotyping for MBL2 alleles (A, B, and C) was performed by restriction fragment-length polymorphism PCR assays, as described elsewhere [15] . Briefly, the PCR amplicon of 349 bp was split and independently digested with the restriction enzymes BanI and MboII. BanI cleaves the A, C, and D alleles into 2 fragments of 260 and 89 bp; the B allele cannot be digested. MboII cleaves the C allele into 2 fragments of 279 and 70 bp, leaving the A, B, and D alleles undigested. To identify the D allele, a PCR amplicon of a 398-bp fragment was amplified with the primers 5'-CTGTAGCTCTCCAGGCATCAACGGCTTCCCAGGCAA-AGATGCG-3' and 5'-TGCTGACTCCATCTCTTCTTTG-3' and digested with HhaI, which cleaves the A allele into 2 fragments of 355 and 43 bp, leaving the D allele uncut. For the promoter variant X/Y, a site-directed mutagenesis PCR was performed with the primers 5'-CAATGCACGGTCCCATTTGTTCTCA-CTGCCGC-3' and 5'-GGACATGGTCCTCACCTTGGTGT-GAG-3', generating a fragment of 328 bp and introducing a restriction site for SacII for recognition of the Y allele. The enzyme cleaves the Y allele into 2 fragments of 296 and 32 bp, leaving the X allele uncleaved.
MBL plasma level determination. MBL levels were determined by means of an MBL oligomer ELISA kit (Antibody Shop), in accordance with the manufacturer's instructions. The microwells were coated with a monoclonal antibody against the MBL carbohydrate-binding domain. Bound MBL was detected with the same antibody labeled with biotin. The lower limit of detection of the assay was 50 ng/mL. MBL plasma levels were tested in 75 HIV-infected children. The median age at which samples were obtained was 87 months (range, 1-201 months), and the median duration of follow-up was 124 months (range, 11-211 months). AIDS developed in 36 (48%) of the 75 children (median time to AIDS, 6 months; range, 1-86 months).
Statistical analysis. Allelic frequencies were obtained by direct gene counting. The fit to Hardy-Weinberg equilibrium and differences in frequency were tested by the Pearson 2 test. To evaluate the independence of the effects of different MBL2 genotypes on the risk of HIV-1 infection, logistic regression analysis was performed, alternatively adjusting the effect of prophylactic treatment with zidovudine. To avoid working with small expected frequencies, the B and D alleles were grouped into a common allele named O for statistical analysis. The Kruskal-Wallis test was applied to detect significant differences in the rank distribution of continuous variables among groups. The association between age and MBL plasma level was evaluated by a Spearman rank correlation statistic-based test. The KaplanMeier method was used to estimate disease progression and survival curves. Relative hazards were calculated for a Cox proportional hazards model, and contrasts between MBL2 genotypes were tested by the Wald test. Patients who did not reach an end point were censored at the time of the last follow-up. The significance level for all tests was .05.
RESULTS
MBL2 genotypes in HIV-exposed children and healthy control subjects. To determine the frequency of MBL2 coding (A, B, C, and D) and noncoding (X and Y) alleles in the Argentinean population, we studied 147 blood donors. All of the alleles except C were found. Table 1 summarizes the MBL2 genotypic and allelic frequencies. In the coding region, 32.6% were A/O heterozygotes and 5.2% were O/O homozygotes, whereas in the noncoding region 22.5% were X/Y heterozygotes and 3.4% were X/X homozygotes. The B and X alleles were commonly found (at frequencies of 0.181 and 0.146, respectively), and the D allele was less frequent (0.033). The MBL2 genotype distributions conformed to the expectations of Hardy-Weinberg equilibrium (P Ͼ .05), indicating that there was no population bias in the control group.
We further investigated whether MBL2 allelic variants might be associated with perinatal HIV-1 transmission. The distribution of MBL2 alleles was analyzed in 161 HIV-infected children and 184 EU children born to HIV-seropositive mothers, a highrisk control group. A high proportion of A/O heterozygotes, mainly due to A/D, and an underrepresentation of X/X homozygotes were observed in EU children, compared with the HIVinfected and control groups (table 1). Compound O/O homozygotes, primarily B/B, were more frequent in the HIV-infected group than in the EU and control groups. Despite these differences, the MBL2 genotype distributions for the coding and noncoding regions did not significantly differ among the groups (P Ͼ .05). All of the MBL2 genotypes studied fitted to HardyWeinberg equilibrium, except for the coding variants in the HIV-infected group; these deviated significantly, with a higher number of homozygous O/O than expected (14 vs. 9; P ϭ .036). This finding might indicate that the O/O homozygotes are at higher risk of HIV-1 acquisition or an early loss of A/O heterozygotes and A/A homozygotes after transmission.
As has been described in other populations, the X allele was in complete linkage disequilibrium with the wild-type coding A allele, generating 3 haplotypes: YA, XA, and YO. In our population, the 6 haplotype pairs identified were YA/YA, YA/YO, XA/ YA, YO/YO, XA/YO, and XA/YA. The haplotype frequencies in the 3 study groups are shown in table 1. The MBL2 haplotype pairs YA/YA, YA/YO, and XA/YA were the most common, with frequencies higher than 14%, whereas XA/XA was the least frequent (Ͻ5%). A/O heterozygotes were more commonly found in the EU group, and XA/XA homozygotes were more frequently in the infected group, although the differences did not reach statistical significance (P ϭ .204).
To evaluate the effect of the different MBL2 genotypes on the risk of HIV-1 infection, a logistic regression analysis was performed. The analysis showed that the genotype XA/XA was associated with an 8-fold risk of HIV-1 vertical transmission (P ϭ .054; odds ratio [ figure 1A . All carriers of the XA/XA genotype but only 40% of A/A, 37% of A/O, and 54% of O/O carriers developed AIDS. Moreover, Kaplan-Meier plots for time to AIDS and modeling by Cox proportional hazards regression showed that children carrying the XA/XA genotype progressed to AIDS significantly faster, with a median AIDS-free period of 33.5 months (P ϭ .026; relative hazard, 2.91 [95% CI, 1.14 -7.47]). Next, we analyzed whether XA haplotype copies had a dose-dependent effect on disease progression. Carriers of the coding A allele were stratified according to the number of copies of the noncoding X variant. As shown in figure 1B , patients who possessed 2 copies of XA haplotype (n ϭ 6) had almost a 3-fold higher risk of progression to AIDS, compared with carriers of 1 or 0 XA copies (P ϭ .037; relative hazard, 2.81 [95% CI, 1.06 -7.44]). Because only 7 patients died during the follow-up period, we were not able to evaluate MBL2 variants in terms of survival time.
Influence of MBL plasma concentration and MBL2 alleles on progression to AIDS. Plasma MBL levels were tested in 75 HIV-infected patients with a median MBL plasma concentration of 1209 ng/mL (interquartile range [IQR], 434 -3756 ng/mL). No association was observed between children's age at the time of sample collection and MBL levels (P ϭ .842, Spearman rank correlation), suggesting no bias. Median MBL plasma concentrations were higher in children with AIDS (n ϭ 36) than in those without (n ϭ 39): 3000 ng/mL (IQR, 844 -4012 ng/mL) versus 875 ng/mL (IQR, 256 -2570 ng/mL) (P ϭ .005). Moreover, in children with higher MBL plasma concentrations, AIDS developed more rapidly (P ϭ .007, Cox proportional hazards regression and Wald test). In addition, as shown in figure 2 , we estimated the prognostic value of MBL plasma concentrations with respect to time to AIDS, with the following cutoff levels: (1) below the lower quartile, (2) 0.25-0.50 quantiles, (3) 0.50 -0.75 quantiles, and (4) above the upper quartile. MBL plasma concentrations above the upper quartile were significantly associated with a rapid progression to AIDS (median, 7 months), with more than a 3-fold higher risk (P ϭ .012, Cox proportional hazards likelihood ratio).
The relationship between MBL levels and MBL2 genotypes was also analyzed. The median MBL plasma concentrations for carriers of A/A, A/O, and O/O genotypes were 3769 ng/mL (IQR, 2805-4150 ng/mL), 832 ng/mL (IQR, 332-1340 ng/mL), and 50 ng/mL (IQR, Ͻ50 to 414 ng/mL), respectively (P Ͻ .001). Undetectable levels (Ͻ50 ng/mL) were found in 10 carriers (13.3%) of the A/O and O/O genotypes. For the haplotype pairs, the median MBL levels were as follows: YA/YA, 3800 ng/mL (n ϭ 12; IQR, 3293-4112 ng/mL); YA/XA, 3880 ng/mL (n ϭ 13; IQR, 3125-4150 ng/mL); XA/XA, 1862 ng/mL (n ϭ 6; IQR, 1518 -4528 ng/mL); YA/YO, 886 ng/mL (n ϭ 22; IQR, 665-2171 ng/mL); XA/YO, 272 ng/mL (n ϭ 10; IQR, 134 -824 ng/mL); and YO/YO, Ͻ50 ng/mL (n ϭ 12; IQR, Ͻ50 to 414 ng/mL) (P Ͻ .0001). The different levels among groups are shown in figure 3 . Genotypes can be roughly divided into 3 groups, according to MBL plasma levels: high (YA/YA, YA/XA, and XA/XA), intermediate (YA/YO), and low (YO/XA and YO/YO). Although XA/XA produced high MBL levels, so did the YA/YA and YA/XA haplotypes, even though carriers of the last 2 showed no evidence of accelerated disease. To test whether the effect of XA/XA genotype on the rate of AIDS progression is independent of MBL concentration, we performed a multivariate analysis. The analysis confirmed a monotonous increase in disease rate with MBL plasma concentrations (P ϭ .008; OR, 1.28 [95% CI, 1.07-1.55]). Even though the trend for XA/XA patients (n ϭ 6) consistently pointed to accelerated disease progression, the evidence was not strong enough to support a mutually independent association of MBL concentration and XA/XA genotype with disease progression (P ϭ .098). Collectively, these results suggest that both MBL plasma concentrations and MBL2 genotypes may be important in the prediction of the risk of AIDS progression. 
DISCUSSION
In the Argentinean population, we found all of the MBL2 coding variants except for the C allele, and frequencies were similar to those reported in white populations [16, 18, 22] . The promoter X variant frequency (15%) was lower than in previous studies in white (24% in Denmark) and African (27% in Kenya) populations. The absence of the C allele was expected, because our population, considered to be white-Hispanic, is composed mainly of descendants of whites from southern European countries, with almost no African admixture. This study is the first report of MBL2 allelic frequencies in the Argentinean population, providing an appropriate frame of reference that may be useful for other disease studies.
The literature on the association of MBL with the progression of HIV infection and AIDS is conflicting, and most studies have evaluated MBL levels and/or MBL2 coding variants in adult cohorts. Homozygosity for the coding variant O/O and low MBL levels have been associated with increased susceptibility to HIV-1 infection in Danish [29] and African [30] patients, but no association was found in a Colombian study [31] . Paradoxically, in a Finnish study, high MBL levels were associated with a higher risk of acquiring HIV-1 infection [32] . Some studies found that patients who are carriers of the B allele and/or have low MBL levels progress more rapidly to death (among HIV-infected adults) [29] or to AIDS (among children) [33] , but once again others found contradictory results [34 -37] . We found an overrepresentation of O/O homozygotes in HIV-1-infected children. This was in agreement with findings in a Brazilian pediatric cohort [38] but differed from those in an Italian pediatric cohort in which no association with MBL2 was observed [33] , although only the B allele was evaluated in a relative small number of patients. Differences in the study populations, including transmission route, ethnicity, sample size, and study design in adult and pediatric cohorts, may account for the discrepancies observed.
In our study, we also evaluated MBL2 noncoding variants and found that the promoter haplotype XA/XA was associated with an 8-fold risk of acquiring HIV-1 and almost a 3-fold risk of progression to pediatric AIDS. Our results suggest that homozygosity for the promoter genotype XA/XA (ϳ3.5% of the general population) has a detrimental effect on HIV-1 vertical transmission and might contribute as a disease modifier of pediatric AIDS.
In general, MBL levels are increased in HIV-infected adult patients [39] and in those with advanced disease [40] , although, in a longitudinal study, no association was found [41] . We observed a wide interindividual variation in MBL plasma levels (from Ͻ50 ng/mL to Ͼ3 g/mL) in HIV-1-infected children. Higher MBL levels were found in patients with AIDS than in those without AIDS, and a faster AIDS progression rate was observed among children with high MBL plasma levels. Indeed, children with MBL levels above the upper quartile (Ͼ3756.5 ng/mL) had more than a 3-fold higher risk of developing AIDS. The relationship between MBL2 genotypes and MBL plasma concentration gives the following hierarchy: YA/YA Ͼ YA/XA Ͼ XA/XA Ͼ YA/O Ͼ XA/O Ͼ O/O. MBL plasma levels Ͼ1 g/mL were found in carriers of the YA/YA, YA/XA and XA/XA genotypes. However, only homozygosity for XA/XA, which showed 2-fold lower MBL plasma levels compared with YA/YA and YA/XA but higher levels compared with coding O variants, was associated with a detrimental effect on HIV-1 disease progression. Similar to our findings, homozygosity for the haplotype XA/XA was found to be a disease modifier in systemic lupus erythematosus, being strongly associated with a higher risk for juvenile systemic lupus erythematosus [12, 13] .
Although MBL is primarily produced in the liver, there is recent evidence for inducible low-grade extrahepatic production of MBL in specific tissues. Jakab et al. [13] have suggested that low production of hepatic MBL due to the down-regulating X promoter allele could be even more evident in the extrahepatic situation, and therefore the associations found with the XA/XA haplotype could be related to tissue-specific synthesis of MBL. The MBL2 gene might be turned on in different compartments in response to different stimuli, and local production of MBL may be biologically relevant to local innate defense [42, 43] . This hypothesis may explain why the association between the XA/XA haplotype and a faster disease rate is not explained solely by MBL plasma levels. Another possibility is that the XA haplotype is a high producer locally or may reflect linkage disequilibrium to another susceptibility locus. Further studies are needed to define the molecular mechanism behind the association between the XA haplotype and the in vivo effect on HIV-1 infection.
